Pancreatic NeoplasmsNCT07843147
Studies of Blood Glucose and the Microbiome in Tumors and Cysts of the Pancreas
An observational study of Pancreatic Neoplasms and Pancreatic Cysts, run by Umeå University.
Trial summary
This prospective, single-center observational study investigates whether continuous glucose monitoring (CGM, 14 days) and gut microbiota composition (from a fecal sample) reveal patterns specific to pancreatic cancer, aiming to contribute to earlier detection and better assessment of disease severity. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Pancreatic Neoplasms, Pancreatic Cysts, Hyperglycemia
- How many people
- 100 participants
- Where
- No sites listed yet
- Study dates
- 1 Oct 2026to 1 Oct 2031
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The study population consists of consecutive adult patients evaluated or treated for pancreatic or periampullary diseases at the Department of Surgery/Cancer Center, Umeå University Hospital, Sweden.
Who may be able to join
- Adults (≥18 years of age).
- Undergoing clinical investigation, follow-up, or treatment for a pancreatic or periampullary condition (malignant or benign/premalignant, including cystic lesions and pancreatitis).
- Willing and able to provide written informed consent for participation in at least one component of the study (continuous glucose monitoring and/or fecal sample collection).
Who cannot join
- -
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
This prospective, single-center observational study investigates whether continuous glucose monitoring (CGM, 14 days) and gut microbiota composition (from a fecal sample) reveal patterns specific to pancreatic cancer, aiming to contribute to earlier detection and better assessment of disease severity. Adult patients under investigation, follow-up, or treatment for benign or malignant pancreatic/periampullary conditions are invited to participate in either or both parts of the study.
Read the detailed description
See Appendix 1 (Research Plan) for a full description of the background, aims, and methods.
- Conditions
- Pancreatic Neoplasms, Pancreatic Cysts, Hyperglycemia, Prediabetes
- Keywords
- continuous glucose monitoring, gut microbiota, pancreatic cancer, biomarker, fecal microbiome
- Medical subject headings
- Pancreatic Neoplasms, Pancreatic Cyst, Hyperglycemia, Prediabetic State
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Patients with pancreatic cancer | Not described | |
| Patients with cysts or other benign pancreatic disease | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
Difference in CGM-derived glycemic variability metrics
Measured: 14 days CGM recording period
Difference in gut microbiota composition
Measured: Single fecal sample
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Sep 2026
- Study start1 Oct 2026 (estimated)
- Primary completion1 Oct 2029 (estimated)
- Study completion1 Oct 2031 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Pancreatic NeoplasmsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Umeå University
- Sponsor type
- University, hospital or other
- Collaborators
- Region Västerbotten
- Responsible party
- Sponsor
- Investigators
- Oskar Franklin, M.D, PhD, Principal investigator, Umeå University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07843147
- Sponsor's protocol ID
- 2026-03261
- Status last verified
- Sep 2026
- First submitted
- 21 Sep 2026
- Last updated
- 25 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: De-identified individual participant data may be shared with qualified researchers upon reasonable request where permitted by applicable legislation, ethical approvals, and participant consent. Data access requests will be reviewed by the study investigators and the responsible institution. Data sharing may require additional ethical approval and a data sharing agreement. Requests that cannot be accommodated under Swedish and EU data protection regulations will not be approved.